Improving survival in patients with trisomy 18

Shoko Tamaki1, Sota Iwatani1, Ayako Izumi1

  • 1Department of Neonatology, Hyogo Prefectural Kobe Children's Hospital Perinatal Center, Kobe, Hyogo, Japan.

Insights

Improved survival rates for trisomy 18 patients were observed, likely due to increased surgical interventions. This study highlights advancements in managing this genetic disorder.

Area of Science:

  • Genetics
  • Pediatrics
  • Medical Research

Background:

  • Trisomy 18 (Edwards syndrome) is a severe genetic disorder with historically low survival rates.
  • Recent changes in perinatal management and treatment strategies may impact patient outcomes.
  • Limited data exists on recent trends in trisomy 18 survival and interventions.

Purpose of the Study:

  • To examine changes in treatment and survival rates for trisomy 18 patients over a decade.
  • To compare outcomes between early and late periods to identify trends.
  • To assess the impact of medical and surgical interventions on trisomy 18 survival.

Main Methods:

  • Retrospective cohort study of 56 trisomy 18 patients admitted within the first week of life.
  • Patients divided into early period (2008-2012) and late period (2013-2017) groups.
  • Comparison of survival rates and surgical intervention proportions between the two periods.

Main Results:

  • One-year survival rates increased from 34.5% (early) to 59.3% (late).
  • Survival to discharge significantly improved from 27.6% to 81.5% (p < 0.001).
  • Surgical intervention rates, particularly for congenital heart defects, rose from 59% to 96% (p = 0.001).

Conclusions:

  • Survival and survival to discharge rates for trisomy 18 patients have significantly improved.
  • Increased surgical interventions, especially for congenital heart defects, are likely drivers of improved outcomes.
  • Findings can aid healthcare providers and families in decision-making for trisomy 18 management.

Related Concept Videos

Treatment Resistant Cancers02:56

Treatment Resistant Cancers

Cancer is the second leading cause of death in the United States. A cancer cell is genetically unstable and hence can mutate faster. They can also modify their microenvironment and escape immune surveillance. The difficulties in treating cancer are further compounded by the emergence of rapid resistance to anticancer drugs. The most common ways to attain resistance in cancer cells include alteration in drug transport and metabolism, modification of drug target, elevated DNA damage response, or...
3.4K
Combination Therapies and Personalized Medicine02:50

Combination Therapies and Personalized Medicine

Combining two or more treatment methods increases the life span of cancer patients while reducing damage to vital organs or tissue from the overuse of a single treatment. Combination therapy also targets different cancer-inducing pathways, thus reducing the chances of developing resistance to treatment.
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...
5.2K
Cancer Survival Analysis01:21

Cancer Survival Analysis

Cancer survival analysis focuses on quantifying and interpreting the time from a key starting point, such as diagnosis or the initiation of treatment, to a specific endpoint, such as remission or death. This analysis provides critical insights into treatment effectiveness and factors that influence patient outcomes, helping to shape clinical decisions and guide prognostic evaluations. A cornerstone of oncology research, survival analysis tackles the challenges of skewed, non-normally...
478
Bone Marrow Sampling and Transplants01:22

Bone Marrow Sampling and Transplants

Bone marrow transplant is a potential cure for several diseases, including cancer and specific genetic disorders. Notably, this procedure is applicable for patients suffering from aplastic anemia, certain types of leukemia, severe combined immunodeficiency disease (SCID), Hodgkin's disease, non-Hodgkin's lymphoma, multiple myeloma, thalassemia, sickle-cell disease, and certain cancers.
The transplant begins with high doses of chemotherapy and radiation treatment, which aim to destroy...
556